Home
Menu
Updates
ARISTO is ranked No. 3 in its Covered market (Source: IQVIA MAT’Feb’25)ARISTO has launched the World’s No.1 probiotic L. rhamnosus GG as ‘ProGG’ under the technical tie-up with the Innovator Chr. Hansen, DenmarkARISTO continues to be No. 5th company in India as per SMSRC prescription audit data (MAT Apr’24 – Feb’25)ARISTO is ranked No. 5 on CAGR (5 years) among the top 15 companies of the India Pharma Market (Source: IQVIA MAT’Feb’25)
Aristo-at-a-galance-1
Aristo-at-a-galance-2

ARISTO at a Glance....

CORPORATE IQVIA DATA

Revenues ( RS. IN CRS. )
:
5700.38
Market Share
:
2.90%
Gain in Market Share%
:
-0.12%
Rx Audit Rank (SMSRC) MAT March’25
:
5
Growth
:
3.47%
CAGR (5 years)
:
10.76%
Rank in Indian Pharma Market
:
11
Covered Market Growth%
:
6.73%
Market Share in Covered Market
:
6.15%
Rank in Covered Market
:
3
Front Line Sales Force
:
5100

Source : Stockist Secondary Audit IMS - MAT MAR'25 Dataset

Cefadrox – CV DT – 250mg, 62.5mg

MOLECULEBRANDSTRENGTHCOMPOSITIONPACK SIZETHERAPY
Cefadroxil, Clavulanic AcidCefadrox - CV DT250mg, 62.5mgEach dispersible uncoated tablet contains: Cefadroxil IP 250mg, Potassium Clavulanate Diluted IP equivalent to Clavulanic acid 62.5mg10'sAnti-Bacterial Oral

© ARISTO Pharmaceuticals Private Limited | Website Maintenance by Website Maintenance Services